Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/11/2023 | $235.00 | Market Outperform | CJS Securities |
NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 3, 2024 S&P SmallCap 600 Addition Protagonist Therapeutics PTGX Health Care S&P SmallCap 600 Deletion Encore Wire WIRE Industrials For more information a
Encore Wire Corporation (NASDAQ Global Select: WIRE) announced today that the Company's Board of Directors has declared a cash dividend. Daniel L. Jones, Chairman, President and Chief Executive Officer of Encore Wire Corporation, said, "This two-cent per share dividend will be paid on July 19, 2024 to stockholders of record at the close of business on July 5, 2024." Encore Wire Corporation is a leading manufacturer of a broad range of copper and aluminum electrical wire and cables, supplying power generation and distribution solutions to meet our customers' needs today and in the future. The Company focuses on maintaining a low-cost of production while providing exceptional customer ser
Encore Wire Corporation (NASDAQ Global Select: WIRE) ("Encore Wire" or the "Company") today announced results for the first quarter of 2024. First Quarter Highlights First Quarter Earnings per diluted share of $3.92 First Quarter Net Income of $63.3 million Gross Profit of 21.5% in the first quarter of 2024; 31.1% in the first quarter of 2023 Copper volume shipped in the first quarter of 2024 increased 19.7% over the first quarter of 2023 Cash on hand of $614.1 million as of March 31, 2024; $560.6 million as of December 31, 2023 Capital expenditures of $34.2 million in the first quarter of 2024 Net sales for the first quarter ended March 31, 2024 were $632.7 million c